The Pharmaceutical Industry’s 10 Biggest R&D Budgets
Innovation is everything when it comes to the pharmaceutical sector. Behind those glorious 75%-plus gross margins associated with branded and patented...
Posts Tagged ‘Lilly Eli & Co (LLY)’
Amgen, Inc. (AMGN), Impax Laboratories Inc (IPXL): Keryx Biopharmaceuticals (KERX)’s Stifel Conference Presentation
Think of The Motley Fool as kind of your TiVo for investment conferences. We’ll help you skip to the good parts and zip past all the rest. There...
Celgene Corporation (CELG), Bristol-Myers Squibb Co (BMY): One Drug Dramatically Reshaping Pancreatic Cancer Treatment
A couple months may not seem like a long time, but when you’re diagnosed with pancreatic cancer, the prospect of a few months makes a huge difference...
MannKind Corporation (MNKD), Seattle Genetics, Inc. (SGEN), Eli Lilly & Co. (LLY): A Pharmacology Primer for Biotech Investors
In pharmacology, we don’t only have to consider the actions of the drug on the body. It is also important to understand the way the body processes...
NPS Pharmaceuticals, Inc. (NPSP), Eli Lilly & Co. (LLY), Alexion Pharmaceuticals, Inc. (ALXN): Three Justifications for the High Cost of Gattex
NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) has priced its Gattex drug for short bowel syndrome, or SBS, at $295,000, expecting to make peak sales of $350...
Express Scripts Holding Company (ESRX), Novo Nordisk A/S (ADR) (NVO), Walgreen Company (WAG): Don’t Mess With This 800-Pound Gorilla in the Pharma Space
Express Scripts Holding Company (NASDAQ:ESRX) — the largest pharmacy benefit manager, or PBM, in America — is also one of the most important...
Pfizer Inc. (PFE), Arena Pharmaceuticals, Inc. (ARNA), VIVUS, Inc. (VVUS): Two Lucrative Drug Markets You Should Avoid
To make a successful drug, it helps to have: A large number of people with the disease. A limited number of successful treatments. You really don’...
Eli Lilly & Co. (LLY), Amgen, Inc. (AMGN), Merck & Co., Inc. (MRK): Where We’re Headed
Over the past couple of months we’ve discussed many of the biggest risk factors associated with some of the leading causes of death in the United...
Will This Destroy MannKind Corporation (MNKD)?
Talk to MannKind Corporation (NASDAQ:MNKD) bulls, and you’ll hear two reasons why its insulin Afrezza is the best thing since sliced bread. The...
Tyson Foods, Inc. (TSN), Merck & Co., Inc. (MRK): Food Companies Suspend Growth Meds for Animals
Top beef producer Tyson Foods, Inc. (NYSE:TSN) has decided to stop buying cattle that are fed the growth additive Zilmax, produced by Merck & Co.,...
MannKind Corporation (MNKD): To Infinity And Beyond?
This week, MannKind Corporation (NASDAQ:MNKD) published a set of frequently asked questions about the recent clinical trials for its inhaled insulin Afrezza...
Pfizer Inc. (PFE): The Procter & Gamble Company (PG)’s Fall Can’t Stop the Dow Jones Industrial Average (.DJI)’s Bounce
Although we don’t believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes — just in case...
Eli Lilly & Co. (LLY), Novartis AG (ADR) (NVS), Shire PLC (ADR) (SHPG): A Closer Look at the Controversial Market Growth of ADHD Treatments
The existence of ADHD, or attention deficit hyperactivity disorder, has been a hot-button topic since the 1970s. On one hand, there are scientists who...
Roche Holding Ltd. (ADR) (RHHBY), Eli Lilly & Co. (LLY): Understanding the Massive Market Potential of Monoclonal Antibodies
Over the past several years, monoclonal antibodies have revolutionized cancer treatments. Monoclonal antibodies are laboratory-produced molecules that...
Tyson Foods, Inc. (TSN), Smithfield Foods, Inc. (SFD): Merck & Co., Inc. (MRK) Buried by Industry Beef
Like a pebble rolling downhill and starting an avalanche, the decision by Tyson Foods, Inc. (NYSE:TSN) to stop buying cattle fattened with the steroid...
Eli Lilly & Co. (LLY), Merck & Co., Inc. (MRK), Sanofi SA (ADR) (SNY): Positive News for This Troubled Pharma Player
Eli Lilly & Co. (NYSE:LLY) recently rose nearly 3% following positive phase 3 results for cancer drug necitumumab. The company had previously halted...
Alkermes Plc (ALKS), Eli Lilly & Co. (LLY), AstraZeneca plc (ADR) (AZN): Tackling Pain and Addiction
Alkermes Plc (NASDAQ:ALKS) is primarily known for its schizophrenia and multiple sclerosis drug treatments. Schizophrenia treatments Risperdal Consta...
Peregrine Pharmaceuticals (PPHM), Sanofi SA (ADR) (SNY): Is This Experimental Lung Cancer Drug Back on Track?
Peregrine Pharmaceuticals (NASDAQ:PPHM), a developmental stage biotech focusing on oncology treatments, recently announced that its lead drug candidate...
Pfizer Inc. (PFE), Eli Lilly & Co. (LLY), Forest Laboratories, Inc. (FRX): The Past, Present, and Future of Alzheimer’s Treatments
Editor’s Note: A previous version of this post incorrectly stated that Eli Lilly’s experimental drug solanezumab is a BACE inhibitor. This has been...
Eli Lilly & Co. (LLY): Is It Destined for Greatness?
Investors love stocks that consistently beat the Street without getting ahead of their fundamentals and risking a meltdown. The best stocks offer sustainable...
Pfizer Inc. (PFE), Novartis AG (ADR) (NVS): Does Incyte Corporation (INCY) Deserve Its New Valuation?
One of the hottest stocks on the market Wednesday was Incyte Corporation (NASDAQ:INCY), a pharmaceutical company specializing in the development of JAK...
Valeant Pharmaceuticals Intl Inc (VRX), GlaxoSmithKline plc (ADR) (GSK) – CAPScall of the Week: Raptor Pharmaceutical Corp. (RPTP)
For years, satirical late-night TV host Stephen Colbert has been running a series on his show called “Better Know a District,” which highlights...
AstraZeneca plc (ADR) (AZN), Eli Lilly & Co. (LLY), MannKind Corporation (MNKD): Three New Diabetes Drugs Possibly on the Way Soon
It’s no wonder that plenty of companies are developing diabetes drugs. There are more than 370 million people with diabetes worldwide. The global...
MannKind Corporation (MNKD), Eli Lilly & Co. (LLY): The Easiest Prediction in Biotech This Summer
MannKind Corporation (NASDAQ:MNKD) is scheduled to release data for two phase 3 trials of its inhaled insulin, Afrezza, this month. Nothing is for certain...
MannKind Corporation (MNKD), Novo Nordisk A/S (ADR) (NVO), Eli Lilly & Co. (LLY): A Good Drug That’s Too Risky to Buy
In a companion article a few days ago, I predicted that MannKind Corporation (NASDAQ:MNKD)‘s extended phase 3 program for its inhaled insulin,...
Eli Lilly & Co. (LLY), Merck & Co., Inc. (MRK), Allergan, Inc. (AGN): Three Companies Working to Make Your Migraines Milder
Do migraines make your life miserable? If so, you’re not alone. The National Headache Foundation (yes, there is such an organization) says that...
Pfizer Inc. (PFE), Merck & Co., Inc. (MRK): Will Zoetis Earnings Deliver on Post-Spinoff Growth?
Zoetis will release its quarterly report on Tuesday, and investors will get their first look at the company as a completely independent business entity...
Eli Lilly & Co. (LLY), Novartis AG (ADR) (NVS): Is This Company Getting Ahead of Itself?
The biotechnology industry is one of the riskiest places to put your money. However, when companies get everything right, the fortunes made there are...
Pfizer Inc. (PFE), Eli Lilly & Co. (LLY), Bristol-Myers Squibb Co (BMY): These Pharmaceutical Giants Are Teetering Dangerously Near The Patent Cliff
In the hunt for sustainable dividend yields, investors have rushed into the stocks of major pharmaceutical companies. These stocks are widely bought for...
Incyte Corporation (INCY) Earnings Cruise on Jakafi Growth
Budding biotech company Incyte Corporation (NASDAQ:INCY), which specializes in developing novel JAK inhibitors, released solid second-quarter earnings...
Intel Corporation (INTC), Chevron Corporation (CVX), Eli Lilly & Co. (LLY): What You Need to Know About Dividends
When it comes to stock investing, conventional thinking dictates that returns are all about capital appreciation. However, for many investors, price appreciation...
Is More Patent Pain Headed Merck & Co., Inc. (MRK)’s Way?
Merck & Co., Inc. (NYSE:MRK) might be one of big pharma’s largest companies, but this health care leader has had a tough go recently. The company...
Three Things You Need to Know From Merck & Co., Inc. (MRK)’s Q2 Earnings
Merck & Co., Inc. (NYSE:MRK) announced its second quarter financial results prior to the market open on Tuesday. Here are the most important things...
AstraZeneca plc (ADR) (AZN) and Bristol Myers Squibb Co. (BMY): 2 Keys to Success for This Diabetes Drug’s Second Chance
If at first you don’t succeed, try, try again. We’ve heard that old saw many times, but it’s good advice. It’s also advice that...
Abbott Laboratories (ABT), Eli Lilly & Co. (LLY): Healthcare Stocks to Consider Buying
Note: This article has been amended to remove TRADJENTA as Eli Lilly & Co. (NYSE:LLY)’s leading products–it is developed and commercialized...
Bristol Myers Squibb Co. (BMY), AstraZeneca plc (ADR) (AZN): Expanding P/E Saved This Pharma Investment
So much for Bristol Myers Squibb Co. (NYSE:BMY)‘s long-term post-Plavix guidance. Three years ago, the company told investors not to worry. It...
Eli Lilly & Co. (LLY), Seagate Technology PLC (STX), Reynolds American, Inc. (RAI): You Should Be Concerned With These 4 Post-Earnings Stocks
Earnings can change the outlook for a company, good or bad, and they can also validate an opinion that you already may have. In the case of these four...
Are Eli Lilly & Co. (LLY) Earnings Headed Down?
Eli Lilly & Co. (NYSE:LLY) will release its quarterly report tomorrow, and recent share-price declines show that investors are somewhat nervous about...
Eli Lilly & Co. (LLY): What Does the Patent Cliff Mean for This Drugmaker?
For Eli Lilly & Co. (NYSE:LLY), history is repeating itself once again. The pharmaceutical company, which became a household name with its antidepressant...
AstraZeneca plc (ADR) (AZN), Eli Lilly & Co. (LLY): The Diabetes Pipeline With a Clog
Big pharma placed its bets on a new class of diabetes drugs called SGLT2. Last year, buzz surrounded late-stage projects from Johnson and Johnson (NYSE...
Alexion Pharmaceuticals, Inc. (ALXN), Eli Lilly & Co. (LLY): Five Drugmakers With a Lot on the Line
You may or may not have heard, but it’s earnings season again. Contrary to popular belief, earnings season does actually take a break for a few...
Three Key Takeaways From Johnson & Johnson (JNJ)’s Q2
Johnson & Johnson (NYSE:JNJ) reported its second quarter on Tuesday, and turned in some positive numbers. Revenue grew 8.5%, year-over-year, up to...
The Future of Sanofi SA (ADR) (SNY)’s Insulin Empire
Sanofi SA (ADR) (NYSE:SNY) appeared at the American Diabetes Association meeting last month, touting data for the new insulin U300 and a combo therapy...
Eli Lilly & Co. (LLY), Teva Pharmaceutical Industries Ltd (ADR) (TEVA): The 3 Most Commonly Diagnosed Mental Disorders
The medical community certainly spends a lot of time and money researching treatments for cardiovascular disease and cancer. It’s not hard to understand...
Could This Safe Play Help Eli Lilly & Co. (LLY)?
Note: This version has been amended to better reflect Victoza’s dosage recommendations. At the American Diabetes Association meeting last month,...
Drug Deal Can Only Help VIVUS, Inc. (VVUS) So Much
VIVUS, Inc. (NASDAQ:VVUS) has found an Italian to help it out. The biotech announced Tuesday that Menarini has agreed to market VIVUS’ erectile...
Could This Safe Play Help Eli Lilly & Co. (LLY)?
At the American Diabetes Association meeting last month, Eli Lilly & Co. (NYSE:LLY) presented promising data for the GLP-1 agonist dulaglutide. GLP...
Allergan, Inc. (AGN): A New Migraine Therapy That Can Address a Major Demand
One-fourth of all migraine patients suffer nasty side effects from the market’s dominant migraine-fighting treatments. Now, a new, convenient inhaled...
Spectrum Pharmaceuticals, Inc. (SPPI): Is This Biotech for Sale?
For the last five years, Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) CEO Rajesh Shrotriya has always insisted that Spectrum Pharmaceuticals, Inc. (NASDAQ...
GlaxoSmithKline plc (ADR) (GSK): Why You Should Buy This European Healthcare Company
Investors who buy stock in the major pharmaceutical companies likely do so because of several factors, including steady growth, modest valuations, and...
